Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

- Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria.

- Acyclovir as acute treatment for herpes outbreaks.

Concurrent Treatment:

Allowed:

- Limited electron-beam radiation therapy to non-marker lesions for treatment of
Kaposi's sarcoma.

Patients must have:

- Documented HIV infection.

- Kaposi's sarcoma.

- No current constitutional signs of HIV disease or AIDS-defining conditions other than
Kaposi's sarcoma.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Active malignancy other than Kaposi's sarcoma, cutaneous basal cell carcinoma, or in
situ carcinoma of the cervix.

- Current significant cardiac disease or anomaly (including prolonged QTC on EKG).

- Abnormal cardio-thoracic ratio on chest x-ray.

Concurrent Medication:

Excluded:

- Antiretroviral agents, including ddI, ddC, AZT, and d4T.

- Immunosuppressive agents.

- Investigational HIV drugs/therapies including vaccines (except those on treatment IND
for approved indications).

- Other anti-Kaposi's sarcoma/HIV drugs.

- Corticosteroids (other than topical).

- Biologic response modifiers.

- Megestrol acetate.

- Agents known to cause neutropenia.

- Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg
sulfamethoxazole thrice weekly.

- Cytotoxic chemotherapy.

Concurrent Treatment:

Excluded:

- Radiation therapy including electron beam irradiation (other than limited
electron-beam radiation to non-marker lesions for treatment of Kaposi's sarcoma).

Patients with the following prior conditions are excluded:

- Prior history of significant cardiac disease or anomaly.

- History of agranulocytosis or severe grade 3 drug-induced neutropenia or documented
abnormalities in granulocyte function.

Prior Medication:

Excluded:

- AZT within 14 days prior to study entry.

- Acyclovir as prophylaxis for herpes within 48 hours prior to study entry.

Excluded within 30 days prior to study entry:

- Interferon.

- Biologic response modifiers.

- Cytotoxic chemotherapy.

Prior Treatment:

Excluded within 30 days prior to study entry:

- Blood or cellular blood product. Active illicit drug abuse (specifically cocaine,
amyl nitrate, heroin, or other cardioactive agents).